These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 3542006)

  • 1. Radioimmunotherapy of malignancy using antibody targeted radionuclides.
    Cobb LM; Humm JL
    Br J Cancer; 1986 Dec; 54(6):863-70. PubMed ID: 3542006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy of solid tumors: from fairytale to reality.
    Adams GP; Weiner LM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):9-11. PubMed ID: 11279802
    [No Abstract]   [Full Text] [Related]  

  • 4. Model based calculation for effective cancer radioimmunotherapy.
    Attard AR; Chappell MJ; Bradwell AR
    Br J Radiol; 1995 Jun; 68(810):636-45. PubMed ID: 7627487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
    Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of radionuclides for tumor therapy.
    Fawwaz RA; Wang TS; Srivastava SC; Hardy MA
    Int J Rad Appl Instrum B; 1986; 13(4):429-36. PubMed ID: 3793498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.
    Lane DM; Eagle KF; Begent RH; Hope-Stone LD; Green AJ; Casey JL; Keep PA; Kelly AM; Ledermann JA; Glaser MG
    Br J Cancer; 1994 Sep; 70(3):521-5. PubMed ID: 8080740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.
    Lucas S; Feron O; Gallez B; Masereel B; Michiels C; Vander Borght T
    Comput Math Methods Med; 2015; 2015():284360. PubMed ID: 26136812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General overview of radioimmunotherapy of solid tumors.
    Navarro-Teulon I; Lozza C; Pèlegrin A; Vivès E; Pouget JP
    Immunotherapy; 2013 May; 5(5):467-87. PubMed ID: 23638743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological advances in radioimmunotherapy.
    Dearling JL; Pedley RB
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):457-69. PubMed ID: 17537620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic immunology of antibody targeted radiotherapy.
    Wong JY
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S8-14. PubMed ID: 16979446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy.
    Jungerman JA; Yu KH; Zanelli CI
    Int J Appl Radiat Isot; 1984 Sep; 35(9):883-8. PubMed ID: 6480148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The radiobiology of targeted radiotherapy.
    Wheldon TE; O'Donoghue JA
    Int J Radiat Biol; 1990 Jul; 58(1):1-21. PubMed ID: 1973428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.
    Steiner M; Neri D
    Clin Cancer Res; 2011 Oct; 17(20):6406-16. PubMed ID: 22003068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunodiagnosis and radioimmunotherapy, 1982.
    Sfakianakis GN; DeLand FH
    J Nucl Med; 1982 Sep; 23(9):840-50. PubMed ID: 6180154
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill.
    Michel RB; Brechbiel MW; Mattes MJ
    J Nucl Med; 2003 Apr; 44(4):632-40. PubMed ID: 12679410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirements for a treatment planning system for radioimmunotherapy.
    DeNardo GL; Raventos A; Hines HH; Scheibe PO; Macey DJ; Hays MT; DeNardo SJ
    Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):335-48. PubMed ID: 3882643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
    Kawashima H
    ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The present role of monoclonal antibodies in the diagnosis and therapy of brain tumours.
    Coakham HB; Kemshead JT
    Wien Klin Wochenschr; 1987 May; 99(11):372-8. PubMed ID: 3617765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.